Demand Fluctuations in Infection-Related Products and Inventory Valuation Losses
First written in FY2024. 3 of 8 entries say "Materialised", first in 2026-05-15. Latest entry: 2026-08-14.
Kohjin Bio moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
The whole theme swung hardest in 2026: 23 of 41 companies on the "Worse" side.
14 other companies' latest entry also says "Restated".
- 2026-08-14RestatedEarnings
「また、感染症関連製品については、過去の需要増加の反動減が続いております。」
感染症関連製品の需要反動減が継続していることを再度記載している。 - FY2026MaterialisedAnnual report
「Demand for COVID-19- and influenza-related products, which had grown substantially in the previous consolidated fiscal year, declined as a reaction to that growth and fell significantly short of plan. In addition, the recognition of inventory disposal losses and inventory write-downs resulted in a difficult earnings environment.」
The decline in demand for infectious-disease-related products following the previous year's surge materialized during the year, and, in addition to lower sales, the Company recognized an inventory write-down of ¥46 million and an inventory disposal loss of ¥107 million. - FY2026-H1WorsenedAnnual report
「Although the number of people infected with COVID-19 had been increasing since August 2025, sales of antigen test kits did not grow as much as in the same period of the previous year and fell short of the initial plan.」
Unlike the increase in sales of related products in the interim period of the previous fiscal year, sales of antigen test kits did not reach the growth seen in the same period of the previous year, even as infections increased, and fell short of the initial plan. - FY2025MitigatedAnnual report
「The Company had recognized an inventory write-down of ¥218 million for infectious-disease-related inventory in the previous consolidated fiscal year, but, as sales volume increased for the reasons described above, it recognized a reversal gain of ¥207 million in the current consolidated fiscal year.」
Demand for infectious-disease-related products recovered, resulting in a reversal gain on part of the inventory write-down recognized in the previous fiscal year. - FY2025-H1Recovery in demand for infectious-disease-related productsAnnual report
「Sales of related products increased significantly as the number of people infected with COVID-19 increased.」
Unlike the demand shortfall and inventory write-down disclosed in the previous fiscal year, the Company disclosed higher sales of related products in the current interim period against a backdrop of an increase in the number of infected people. - FY2024First statedAnnual report
「Sales volume fell significantly short of the initial plan, and the Company recognized an inventory write-down of ¥218 million for infectious-disease-related inventory in the fiscal year ended March 2024.」
Changes in demand after the reclassification of COVID-19 to Category V actually occurred, and inventory write-downs were recognized for antigen test kits and other products.